Drug Trial Radar · NCT04452955
A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors
Last checked: Nov 20, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
51
Actual
Start
Dec 12, 2020
Primary completion
Dec 1, 2026
Study completion Dec 1, 2026
Sponsor
- Lead sponsor
- Intra-IMMUSG Pte LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Jul 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, Phase 2, open-label, single dose level study of PRL3-zumab monotherapy in patients with unresectable or metastatic solid tumor.
Conditions
- Solid Tumor
Interventions
PRL3-zumabBiological
Starting dose of 6 mg/kg will be administered as IV infusion over 60 minutes every 2 weeks (±2 days)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS)Time frame: From first dose of study drug until disease progression or end of treatment, whichever comes first
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
HonorHealth Research
Scottsdale, Arizona
St. Jude Medical Center
Fullerton, California
The Angeles Clinic
Los Angeles, California
Norton Healthcare
Louisville, Kentucky
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.